Disorders of sex development : timing of diagnosis and management in a single large tertiary center by Kohva, E. et al.
7:4 595–603E Kohva et al. DSDs: timing of diagnosis and 
management
RESEARCH
Disorders of sex development: timing of 
diagnosis and management in a single large 
tertiary center
E Kohva1,2, P J Miettinen1, S Taskinen1,3, M Hero1, A Tarkkanen1,2 and T Raivio1,2
1Children’s Hospital, Pediatric Research Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
2Faculty of Medicine, Department of Physiology, University of Helsinki, Helsinki, Finland
3Department of Pediatric Surgery, Children’s Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
Correspondence should be addressed to T Raivio: taneli.raivio@helsinki.fi
Abstract
Background: We describe the phenotypic spectrum and timing of diagnosis and 
management in a large series of patients with disorders of sexual development (DSD) 
treated in a single pediatric tertiary center.
Methods: DSD patients who had visited our tertiary center during the survey period 
(between 2004 and 2014) were identified based on an ICD-10 inquiry, and their 
phenotypic and molecular genetic findings were recorded from patient charts.
Results: Among the 550 DSD patients, 53.3% had 46,XY DSD; 37.1% had sex 
chromosome DSD and 9.6% had 46,XX DSD. The most common diagnoses were Turner 
syndrome (19.8%, diagnosed at the mean age of 4.7 ± 5.5 years), Klinefelter syndrome 
(14.5%, 6.8 ± 6.2 years) and bilateral cryptorchidism (23.1%). Very few patients with 
46,XY DSD (7%) or 46,XX DSD (21%) had molecular genetic diagnosis. The yearly rate of 
DSD diagnoses remained stable over the survey period. After the release of the Nordic 
consensus on the management of undescended testes, the age at surgery for bilateral 
cryptorchidism declined significantly (P < 0.001).
Conclusions: Our results show that (i) Turner syndrome and Klinefelter syndrome, the 
most frequent single DSD diagnoses, are still diagnosed relatively late; (ii) a temporal 
shift was observed in the management of bilateral cryptorchidism, which may favorably 
influence patients’ adulthood semen quality and (iii) next-generation sequencing 
methods are not fully employed in the diagnostics of DSD patients.
Background
Disorders of sexual development (DSD) are congenital 
conditions in which the chromosomal, anatomic or 
gonadal sex development is atypical (1). Today, DSD 
is classified into three major categories by the patient’s 
karyotype: sex chromosome DSD, 46,XY DSD and 46,XX 
DSD (1). The phenotypic spectrum of DSD is wide, and it 
can manifest as a complete sex reversal, a solitary genital 
abnormality or it can be a part of a syndrome affecting 
other organ systems (2). The etiology of DSD is multifaceted 
and can be caused by genetic and environmental factors; 
especially, hypospadias and undescended testes have 
been linked to the actions of environmental agents (3). 
A family history with genital abnormalities, delayed 
puberty, infertility, stillbirths or multiple miscarriages 
should lower the threshold for molecular genetic 
investigations (4). A newborn with ambiguous genitalia 
requires evaluation by a multidisciplinary team that aims 
to determine the sex of rearing, and eventually designs a 
long-term management plan in close co-operation with 
the patient and the family (1). It is generally agreed that 
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timely diagnosis and management are important as they 
potentially prevent adverse health outcomes and improve 
long-term, health-related quality of life (5, 6, 7, 8, 9, 10).
There are currently only a handful of systematic and 
comprehensive reports on the etiology and management of 
DSD patients (11, 12, 13, 14, 15, 16, 17). At the same time, 
there is a vivid ongoing global debate on the treatment 
policies of these patients (4, 14, 18, 19, 20). The first step 
toward evidence-based, optimal care of this patient group 
would be to describe the current status of diagnostics and 
management in pediatric tertiary centers. In this study, we 
describe the phenotypic spectrum and molecular genetic 
findings of DSD patients treated at the Helsinki University 
Hospital between 2004 and 2014, with special attention 
on the timing of diagnosis and management of the most 
prevalent DSDs.
Patients and methods
We performed an ICD-10 code-based inquiry covering 
the years from 2004 to 2014 to the electronic patient 
information system of the Helsinki University Hospital, 
the tertiary center of the Helsinki metropolitan area 
(catchment area 1.2 million people in 2014, 0.3 million of 
which were children and adolescents 0–20 years old (21)) 
also nationally responsible for treating severe and rare 
illnesses. We included diagnoses describing phenotypes 
with deviations in chromosomal, gonadal or phenotypic 
sexual development. To examine the relation of minor 
anatomic deviations to actual DSDs, we accepted a 
wide range of diagnoses (i.e. distal hypospadias and/or 
unilateral cryptorchidism) in the search (Table  1). We 
identified altogether 3206 patients who had visited the 
Pediatric, Pediatric Endocrine and/or Pediatric Surgical 
Clinics for the evaluation of treatment of DSD or a minor 
anatomic deviation. The selection of these outpatient 
clinics was based on their clinical practice: every DSD 
patient visits either pediatrician, pediatric endocrinologist 
or pediatric surgeon. Data from other departments (i.e. 
genetics) were utilized, if available. In the more thorough 
examination, we included patients with ICD-10 diagnoses 
describing DSD phenotypes as defined by the LWPES/ESPE 
consensus group in 2006 (1), and hence, also accepted 
bilateral cryptorchidism and penoscrotal or perineal 
hypospadias. We reviewed the electronic patient records 
of these patients (n = 885) for clinical features, karyotype 
and molecular genetics to verify their diagnoses and record 
their family anamnesis (Fig. 1). The date of diagnosis was 
defined as the first remark by a pediatric endocrinologist 
or a pediatric surgeon in the patient data system on either 
clinical or molecular genetic DSD diagnosis. Patients over 
20 years old and patients with unilateral cryptorchidism, 
distal hypospadias, epispadias, chordee, cloaca, congenital 
rectovaginal fistula, imperforate hymen, bifid clitoris or 
fusion of labia were excluded from the analyses. Boys with 
congenital adrenal hyperplasia (CAH) were not considered 
DSD patients since no DSD phenotype was present.
We paid special attention to patients who had either 
Turner syndrome (TS) or Klinefelter syndrome (KS). The 
ICD-10 inquiry returned originally 134 patients with 
TS diagnosis. Manual verification of the patient records 
revealed, however, that 25 of them did not meet the 
definition for TS (9) and therefore 109 TS patients were 
included in the analyses. Similarly, we excluded 5 of the 
85 KS patients identified by the original ICD-10 inquiry, 
as they were found not to meet the criteria for KS (22). 
The age at diagnosis was available for 90% (n = 98) of TS 
patients and 85% (n = 68) KS patients. Approximately half 
of TS (51%) and KS (55%) patients were diagnosed during 
the study period.
To study the management of bilateral cryptorchidism, 
we evaluated all 46,XY DSD patients retrieved by the 
ICD-10 search (Table 1). The patient records of boys referred 
for isolated bilateral cryptorchidism or a more complex 
phenotype accompanied by bilaterally undescended testes 
were reviewed. The age at bilateral orchiopexy or the first 
of the two unilateral orchiopexies was recorded for each 
boy and used in subsequent analyses.
Statistical analyses
Correlations between variables were assessed with 
Spearman rank correlation analysis. Mann–Whitney 
U test and chi-square test were used to compare the ages 
of boys with bilateral cryptorchidism operated between 
2004 and 2007 or 2008 and 2014. The data in the text 
are presented with a mean ± s.d. and the data in the tables 
as median (range) unless otherwise stated. P < 0.05 was 
accepted to indicate statistical significance.
Results
Phenotypic spectrum of DSD patients and timing 
of diagnosis
We identified 3206 patients who were evaluated for one or 
multiple ICD-10 diagnosis of interest in either Pediatric, 
Pediatric Endocrine and/or Pediatric Surgery Outpatient 
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Clinics at the Helsinki University Hospital between 2004 
and 2014. Over two-thirds of these patients (72%) had 
minor deviations of the genitourinary tract that are not 
classified as DSDs (Fig. 1 and Table 1). Patients with a DSD 
diagnosis (n = 550) were divided into three karyotype-
based subgroups as suggested in the Chicago consensus 
statement (1); 53.3% had 46,XY DSD; 37.1% had sex 
chromosome DSD and 9.6% had 46,XX DSD (Fig.  1). 
Only 21% of 46,XX DSD patients and 7% of 46,XY DSD 
patients had a molecular genetic diagnosis, and none 
of those were made with next-generation sequencing 
methods. Even in patients with a distinct phenotype, 
such as persistent Müllerian duct syndrome, the diagnosis 
was seldom confirmed genetically. Age at diagnosis 
was available for 75% of 46,XY DSD patients, 86% of 
46,XX DSD patients and 87% of sex chromosome DSD 
Table 1 ICD-10 diagnoses included in the inquiry.
46,XY DSD
  E34.5 Androgen insensitivity syndrome
  Q53.2 Undescended testicle, bilateral
  Q54.2 Hypospadias, penoscrotal
  Q54.3 Hypospadias, perineal
  Q55.00 Absence and aplasia of testis
  Q55.01 Anorchia
  Q56.1 Male pseudohermaphroditism, not elsewhere classified
  Q97.3 Female with 46,XY karyotype
46,XX DSD
  Q52.0 Congenital absence of vagina
  Q52.1 Doubling of vagina
  Q56.2 Female pseudohermaphroditism, not elsewhere classified
  Q98.3 Other male with 46,XX karyotype
  E25.00 Salt-losing congenital adrenal hyperplasia
  E25.01 Congenital adrenal hyperplasia
Sex chromosome DSD
  Q96.0-Q96.9 Turner syndrome and variants
  Q97.0-Q97.9 Other sex chromosome abnormalities, female phenotype, not elsewhere classified
  Q98.0,Q98.1  
  Q98.2,Q98.4 Klinefelter syndrome and variants
  Q98.5-Q98.9 Other sex chromosome abnormalities, male phenotype, not elsewhere classified
Unspecified DSD
  E25.9 Adrenogenital disorder, unspecified
  Q56.0 Hermaphroditism, not elsewhere classified
  Q56.3 Pseudohermaphroditism, unspecified
  Q56.4 Indeterminate sex, unspecified
Other diagnoses
  Q53.0 Ectopic testis
  Q53.1 Undescended testicle, unilateral
  Q53.9 Undescended testicle, unspecified
  Q54.0 Hypospadias, balanic
  Q54.1 Hypospadias, penile
  Q54.4 Congenital chordee
  Q54.8 Other hypospadias
  Q54.9 Hypospadias, unspecified
  Q55.1 Hypoplasia of testis and scrotum
  Q55.20 Retractile testis
  Q55.28 Unspecified congenital malformations of testis and scrotum
  Q55.6 Other congenital malformations of penis
  Q55.8 Other specified congenital malformations of male genital organs
  Q55.9 Congenital malformation of male genital organ, unspecified
  Q52.2 Congenital rectovaginal fistula
  Q52.3 Imperforate hymen
  Q52.4 Other congenital malformations of vagina
  Q52.5 Fusion of labia
  Q52.8 Other specified congenital malformations of female genitalia
  Q52.9 Congenital malformation of female genitalia, unspecified
  Q64.1 Exstrophy of urinary bladder
  Q43.7 Persistent cloaca
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patients. Table 2 shows detailed distribution and timing 
of diagnoses among these DSD patients; most common 
diagnoses were bilateral cryptorchidism (23.1%), TS 
(19.8%) and KS (14.5%). The mean age at diagnosis was 
2.2 ± 3.8  years for 46,XY DSD, 2.4 ± 4.6  years for 46,XX 
DSD and 5.3 ± 5.8  years for sex chromosome DSD. In 
the majority of patients with 46,XY DSD or 46,XX DSD 
the diagnosis, based on phenotype or molecular genetic 
finding, was made immediately after birth, apart from 
46,XX DSD patients expressing SRY and those presenting 
DSD as part of a syndrome.
Consanguinity was seldom reported in our data: 
only in two families, the parents were either first or 
second cousins. Two families with multiple DSD cases 
were identified. One family presented with several cases 
of persistent Müllerian duct syndrome. In the other 
family, there were two brothers with a DSD phenotype 
of unknown etiology (one brother had a micropenis with 
proximal hypospadias and a vaginal remnant and the 
other proximal hypospadias). In addition, three families 
where the DSD patient’s sibling had a minor anatomic 
deviation were identified.
We next investigated the annual number of new 
DSD patients between 2004 and 2014 (n = 290), excluding 
patients who had been diagnosed before 2004 and 
had follow-up visits during the survey period. The 
annual number of new DSD patients remained stable 
(26 ± 7 patients per year; mean ± s.d., range 10–40) and 
did not correlate with time (r = 0.18, P = 0.6, n = 11). No 
significant trends in the annual number of patients were 
observed either when estimated separately in subgroups 
of 46,XY DSD (range 5–24, r = 0.31, P = 0.4, n = 11), sex 
chromosome DSD (range 5–15, r = −0.43, P = 0.18, n = 11) 
and 46,XX DSD (range 0–6, r = −0.50, P = 0.12, n = 11).
Timing of diagnosis in sex chromosome DSDs: 
Turner syndrome and Klinefelter syndrome
Our data allowed us to estimate the age at diagnosis of (TS) 
and (KS) (Fig. 2). For the 80 boys with KS, the diagnosis 
was set at the mean age of 6.8 ± 6.2 years mostly due to 
specific language impairment and/or learning difficulties 
(40%), delayed motor development (13%) or small testicles 
(11%). Twelve boys were diagnosed already before birth 
(Fig. 2). Boys referred for evaluation due to developmental 
issues were aged 8.0 ± 3.5  years, and boys detected due 
to small testicular size 15.8 ± 1.3  years. Klinefelter boys 
diagnosed after birth were most frequently referred from 
Figure 1
Inclusion criteria and outcomes. Patients retrieved 
from the ICD-10 inquiry (n = 3206) and DSD 
patients (n = 550) included in the analyses, divided 
into three subgroups based on ‘Consensus 
statement on management of intersex  
disorders’ (1).
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the local healthcare center (24%), maternity hospital (9%) 
or department of pediatric neurology (9%).
The girls with TS (n = 109) were diagnosed at the 
mean age of 4.7 ± 5.5  years. The age distribution was 
skewed as twenty-five girls were diagnosed prenatally, 
and, in 47% of the cases, diagnosis was reached by the 
age of one year (Fig.  2). Turner girls diagnosed after 
birth were most frequently referred by child health 
care clinic (19%), maternity hospital (16%) or another 
hospital district (6%). The main complaint (41% of all 
cases) was delayed growth. There were no significant 
trends in the age at diagnosis in either KS or TS patient 
groups between 2004 and 2014 (KS range 0–17  year, 
r = 0.05, P = 0.75, n = 44; TS range 0–17  year, r = 0.003, 
P = 0.98, n = 56).
Timing of management in bilateral cryptorchidism
Finally, we reviewed the changes in the management of 
cryptorchidism by estimating the age at operation for 
bilateral cryptorchidism before (years 2004–2007) and 
following the release of the Nordic consensus (years 
2008–2014) on treatment of undescended testes (8). 
Altogether, during the whole study period (2004–2014), 
142 patients were operated and the average age of 
operation for bilateral cryptorchidism was 45.1 ± 44.8 
months. The annual number of operated patients (range 
8–17) did not increase significantly during the survey 
period (R = 0.41, P = 0.21, n = 11). However, the age at 
operation declined after the release of the consensus from 
54.5 ± 43.0  months to 41.1 ± 45.3  months (P = 0.0001). 









(A) Disorders of gonadal development
  1. Gonadal regression 27 (4.9) 0.84 (0.01–14.9) 0
  2. Ovotesticular DSD 2 (0.4) 7.9 (0.04–15.7) 0
(B) Disorders in androgen synthesis or action
  1. Androgen biosynthesis defect (3BHSD) 1 (0.2) NA 0
  2. Defect in androgen action (AIS) 5 (0.9) 7.7 (0–15.3) 20
  3. Disorders of AMH of AMH-receptor (persistent Müllerian  
duct syndrome)
7 (1.3) 0.7 (0–2.4) 29
(C) Other
  1. Unknown male undermasculinization
  Bilateral cryptorchidism 125 (22.7) 0.9 (0–16.1) 9
  Severe hypospadias 55 (10.0) 0.01 (0–1.7) 0
  Severe hypospadias and bilateral cryptorchidism 16 (2.9) 0.02 (0–0.04) 0
  Micropenis 5 (0.9) 0.01 (0–10.6) 0
  Micropenis and bilateral cryptorchidism 6 (1.1) 0.1 (0–10.5) 20
  Micropenis and severe hypospadias 8 (1.5) 0.01 (0–0.4) 0
  Micropenis, bilateral cryptorchidism and severe hypospadias 4 (0.7) 0 (0–0.1) 0
  2. Part of a syndrome (e.g. Prune Belly, Prader–Willi, Noonan) 19 (3.5) 0.02 (0–11.5) 42
  3. Cloacal extrophy 13 (2.4) 0.0 0
46,XX DSD
(A) Disorders of gonadal development
  1. Ovotesticular DSD 1 (0.2) 0.0 0
  2. SRY + 4 (0.7) 6.3 (0.3–18.1) 100
(B) Androgen excess
  1. CAH 31 (5.6) 0.0 (0–8.8) 23
(C) Other
  1. Congenital structural abnormalities (e.g. vagina duplex,  
vaginal atresia, clitoris hyperplasia)
5 (0.9) 0.05 (0–10.6) 0
  2. Part of a syndrome (e.g. MRKH, HFGS) 6 (1.1) 6.4 (0–15.4) 0
  3. Cloacal extrophy 6 (1.1) 0.0 0
Sex chromosome DSD
(A) Turner syndrome and variants 109 (19.8) 2.1 (0–17.0)
(B) Klinefelter syndrome and variants 80 (14.5) 6.7 (0–17.4)
(C) 45,X/ 46,XY mixed gonadal dysgenesis, ovotesticular DSD 14 (2.5) 0.0 (0–10.1)
(D) Other
  Structural anomaly of Y chromosome and testis retention 1 (0.2) 0.07
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Indeed, before the Nordic consensus statement, 
all bilateral cases (n = 42) were operated after the age of 
1 year but after 2007, almost one-third (28 of 100 boys) 
was operated before the age of 1 year (P = 0.0001, Fig. 3). 
To exclude boys with acquired cryptorchidism and cases 
of congenital cryptorchidism missed in early childhood, 
we limited the analysis to those boys operated before the 
age of three (23). In this subanalysis, the age at operation 
had declined from 24.5 ± 5.4  months in boys operated 
between 2004 and 2007 to 13.7 ± 5.3  months in those 
operated after 2007 (P < 0.0001).
Discussion
Attempts to estimate the etiological distribution of DSDs 
according to the 2006-launched DSD classification system 
are few. In our series, approximately half of the patients 
had 46,XY DSD, whereas only one-tenth (9.6%) had 46,XX 
DSD. The proportion of 46,XY DSD patients is similar to 
the results reported from Turkey (47%) (12), South Africa 
(57%) (13) and North India (52.5%) (17), and somewhat 
lower than has been reported from Indonesia (68%) (16). 
On the other hand, our series contained more cases with 
sex chromosome DSDs than the previously mentioned 
reports, which may reflect differences in prenatal 
screening policies. Of note, in a recent Danish nationwide 
study, the estimated prevalence of androgen insensitivity 
syndrome was 2.3 per 100,000 live born females (24), 
which appears close to our frequency estimate based 
on the current catchment area of our tertiary center. In 
our study, congenital adrenal hyperplasia (CAH) was 
expectedly the most common cause of 46,XX DSD. After 
the implementation of the newborn screening in Finland 
Figure 2
Percentage of TS (n = 98) and KS (n = 68) patients 
diagnosed per age group. Data obtained from 
patients visiting the outpatient clinics of a single 
tertiary center between 2004 and 2014 whose 
age at diagnosis was available.
Figure 3
Age at orchiopexy. Age at bilateral orchiopexy or 
first of the two unilateral orchiopexies in a single 
tertiary center in 142 boys operated between 
2004 and 2014. 42 boys were operated between 
2004 and 2007 before the release of the Nordic 
consensus on treatment of undescended testes (8) 
and 100 boys thereafter.
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in 2015, six new CAH patients have been diagnosed by 
it. We anticipate that screening leads to better diagnostic 
yield and conceivably better care for this patient group in 
the future.
Since early diagnosis of DSD is considered important 
(7, 25, 26), the efficacy of the diagnostic procedures of 
most frequent patient groups merits evaluation. The mean 
age at diagnosis of TS patients in our series was 4.7 years, 
a result similar to the findings reported from the United 
States and Spain (26, 27). A quarter of our TS patients was 
diagnosed prenatally, based on the voluntary, combined 
first trimester screening (a nuchal translucency scan 
and maternal serum screening followed by a prenatal 
chromosome test, if necessary). After birth, the most 
frequent symptom guiding to diagnosis was short stature 
(41%), the leading clinical cue also in other studies (26, 
27). The diagnosis of KS patients in our series was even 
further delayed, and the diagnosis was typically suspected 
during childhood due to developmental problems, and 
during adolescence due to small testicular size. If the 
frequency of KS was 1/667 male births in our area (28), 
we could roughly estimate that, between 2004 and 2006, 
~20–30% of the boys with KS were diagnosed before the 
age of 8 years. This low diagnostic yield is in agreement 
with the Danish data suggesting that only 10% of Danish 
KS patients are diagnosed before the age of 14  years 
(29). One possibility to expedite diagnostics would be to 
include sex chromosome abnormalities in the national 
newborn screening programs, an idea that has been well-
taken by parents of KS patients and pediatricians (10, 30). 
Also peer groups of TS (e.g. Turner Syndrome Society of 
the United States) are in favor of diagnosing TS as early 
as possible in order to anticipate the possible need of 
services required for variable defects in childhood (31). 
On the other hand, many pregnancies, in which TS is 
prenatally diagnosed, are currently terminated, although 
the severity of the TS phenotype is hard to predict and a 
postnatal re-evaluation of chromosomes is needed for an 
accurate diagnosis (9, 31).
The timing of orchiopexy is highly variable, and for 
example, 95% of surgeries were performed after the first 
year of life in German hospitals (32), and in Singapore, the 
corresponding number was 70% (33). Nordic guidelines 
for the treatment of cryptorchidism were renewed at 2007 
and accordingly the age for orchiopexy was advanced to 
6–12 months (8). We tested whether implementation of the 
guideline in our tertiary center functions as an indicator 
for standard of care. Between 2004 and 2007, before the 
release of the Nordic consensus statement (8), not a single 
boy with bilateral cryptorchidism was operated before the 
age of one year in our hospital, whereas thereafter, the age 
at orchiopexy has decreased at least by 10 months. Our 
finding is in line with the results published from Sweden 
and Norway (34, 35).
In this cohort, 21% of patients with 46,XX DSD and 
only 7% of 46,XY DSD were diagnosed genetically. In the 
largest patient group of 46,XX DSD, CAH, the current 
standard of diagnostics is still based on steroid hormone 
and other biochemical analyses instead of molecular 
genetics (36). For 46,XY DSD boys, it seems that the 
etiology remains largely unknown in the clinical setting. 
In the research setting, however, the overall genetic 
diagnostic rate achieved with a targeted DSD gene panel, 
can increase up to 43% (37). An accurate molecular genetic 
diagnosis is probably valuable in planning the long-term 
treatment of the patient, although more research is needed 
to show if the ever more precise diagnostics is associated 
with beneficial changes in clinical practice from the 
patient’s perspective (38). While awaiting such evidence, 
it is still reasonable to conclude that the molecular genetic 
diagnostic rate should be improved by applying NGS 
methodology.
Our retrospective study has certain limitations. The 
ICD-10 classification has multiple different diagnosis 
codes describing the same phenomenon. To overcome 
this, we evaluated the patient records and chose the 
diagnostic code, which best described the patient’s 
phenotype. Moreover, often there are no specific ICD-10 
codes reserved for rare genetic diseases.
Conclusions
We present data from one of the largest series of DSD 
patients to date. Analysis of patients with chromosomal 
DSD shows that patients with TS or KS are diagnosed 
relatively late and often the initiative for the diagnostic 
workup is related to special needs of the patients (KS) 
or deceleration of growth (TS). It is feasible that age at 
diagnosis in patients with TS or KS and the age at operation 
of bilateral cryptorchidism could serve as indices for 
monitoring the diagnostic efficiency and management 
of DSD patients within and between different tertiary 
centers providing care for this vulnerable patient group.
Declaration of interest
The authors declare that there is no conflict of interest that could be 
perceived as prejudicing the impartiality of the research reported.
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0070
http://www.endocrineconnections.org ©2018 The authors
Published by Bioscientifica Ltd




This work was supported by the Finnish foundation for Pediatric Research, 
Academy of Finland and Emil Aaltonen foundation.
Author contribution statement
All authors have provided substantial input to the concept of the study 
and drafting the article. E K, P M and T R designed the study. E K and A T 
collected the data. P M, S T, M H and T R advised in interpreting the patient 
data. E K analyzed the data and wrote the first draft of the manuscript. All 
authors contributed in revising and editing the manuscript.
Acknowledgements
The authors acknowledge Prof. Jorma Toppari, MD, PhD, for reading and 
commenting the manuscript.
References
 1 Hughes IA, Houk C, Ahmed SF & Lee PA. Consensus statement on 
management of intersex disorders. Journal of Pediatric Urology 2006 2 
148–162. (https://doi.org/10.1016/j.jpurol.2006.03.004)
 2 Hutson JM, Grover SR, O’Connell M & Pennell SD. Malformation 
syndromes associated with disorders of sex development. Nature 
Reviews Endocrinology 2014 10 476–487. (https://doi.org/10.1038/
nrendo.2014.83)
 3 Bonde JP, Flachs EM, Rimborg S, Glazer CH, Giwercman A, Ramlau-
Hansen CH, Hougaard KS, Høyer BB, Hærvig KK, Petersen SB, et al. 
The epidemiologic evidence linking prenatal and postnatal exposure 
to endocrine disrupting chemicals with male reproductive disorders: 
a systematic review and meta-analysis. Human Reproduction Update 
2016 23 104–125. (https://doi.org/10.1093/humupd/dmw036)
 4 Ahmed SF, Achermann JC, Arlt W, Balen A, Conway G, Edwards Z, 
Elford S, Hughes IA, Izatt L, Krone N, et al. Society for Endocrinology 
UK guidance on the initial evaluation of an infant or an adolescent 
with a suspected disorder of sex development (Revised 2015). Clinical 
Endocrinology 2015 84 771–788. (https://doi.org/10.1111/cen.12857)
 5 Nordenström A, Röhle R, Thyen U, Bouvattier C, Slowikowska-
Hilczer J, Reisch N, et al. Hormone therapy and patient satisfaction 
with treatment, in a large cohort of diverse disorders of sex 
development. Clinical Endocrinology 2018 88 397–408. (https://doi.
org/10.1111/cen.13518)
 6 Quinton R, Mamoojee Y, Jayasena CN, Young J, Howard S, Dunkel L, 
Cheetham T, Smith N & Dwyer AA. Society for Endocrinology 
UK guidance on the evaluation of suspected disorders of sexual 
development: emphasising the opportunity to predict adolescent 
pubertal-failure through a neonatal diagnosis of absent mini-puberty. 
Clinical Endocrinology 2016 86 305–306. (https://doi.org/10.1111/
cen.13257)
 7 Cassia Amaral R, Inacio M, Brito VN, Bachega TASS, Oliveira AA, 
Domenice S, Denes FT, Sircili MH, Arnhold IJ, Madureira G, et al. 
Quality of life in a large cohort of adult Brazilian patients with 46,XX 
and 46,XY disorders of sex development from a single tertiary centre. 
Clinical Endocrinology 2015 82 274–279. (https://doi.org/10.1111/
cen.12572)
 8 Ritzén EM, Bergh A, Bjerknes R, Christiansen P, Cortes D, Haugen SE, 
Jörgensen N, Kollin C, Lindahl S, Läckgren G, et al. Nordic consensus 
on treatment of undescended testes. Acta Paediatrica 2007 96 
638–643. (https://doi.org /10.1111/j.1651-2227.2006.00159.x)
 9 Bondy CA & Turner Syndrome Study Group. Care of girls and 
women with Turner syndrome: a guideline of the Turner Syndrome 
Study Group. Journal of Clinical Endocrinology and Metabolism 2007 92 
10–25. (https://doi.org/10.1210/jc.2006-1374)
 10 Gies I, Tournaye H & De Schepper J. Attitudes of parents of 
Klinefelter boys and pediatricians towards neonatal screening and 
fertility preservation techniques in Klinefelter syndrome. European 
Journal of Pediatrics 2016 175 399–404. (https://doi.org/10.1007/
s00431-015-2657-7)
 11 Lux A, Kropf S, Kleinemeier E, Jürgensen M, Thyen U & DSD 
Network Working Group. Clinical evaluation study of the German 
network of disorders of sex development (DSD)/intersexuality: 
study design, description of the study population, and data quality. 
BMC Public Health 2009 9 110. (https://doi.org/10.1186/1471-2458-
9-110)
 12 Erdoğan S, Kara C, Uçaktürk A & Aydın M. Etiological classification 
and clinical assessment of children and adolescents with disorders of 
sex development. Journal of Clinical Research in Pediatric Endocrinology 
2011 3 77–83. (http://doi.org/10.4274/jcrpe.v3i2.16)
 13 Ganie Y, Aldous C, Balakrishna Y & Wiersma R. Disorders of 
sex development in children in KwaZulu-Natal Durban South 
Africa: 20-year experience in a tertiary centre. Journal of Pediatric 
Endocrinology and Metabolism 2016 30 11–18. (https://doi.
org/10.1515/jpem-2016-0152)
 14 Jaruratanasirikul S & Engchaun V. Management of children with 
disorders of sex development: 20-year experience in southern 
Thailand. World Journal of Pediatrics 2014 10 168–174. (https://doi.
org/10.1007/s12519-013-0418-0)
 15 Al-Jurayyan NAM. Ambiguous genitalia: two decades of 
experience. Annals of Saudi Medicine 2011 31 284–288. (https://doi.
org/10.4103/0256-4947.81544)
 16 Juniarto AZ, van der Zwan YG, Santosa A, Ariani MD, Eggers S, 
Hersmus R, Themmen AP, Bruggenwirth HT, Wolffenbuttel KP, 
Sinclair A, et al. Hormonal evaluation in relation to phenotype and 
genotype in 286 patients with a disorder of sex development from 
Indonesia. Clinical Endocrinology 2016 85 247–257. (https://doi.
org/10.1111/cen.13051)
 17 Walia R, Singla M, Vaiphei K, Kumar S & Bhansali A. Disorders of 
sex development: a study of 194 cases. Endocrine Connections 2018 7 
364–371. (https://doi.org/10.1530/EC-18-0022)
 18 Hiort O, Wünsch L, Cools M, Looijenga L & Cuckow P. 
Requirements for a multicentric multidisciplinary registry 
on patients with disorders of sex development. Journal of 
Pediatric Urology 2012 8 624–628. (https://doi.org/10.1016/j.
jpurol.2012.09.004)
 19 Pasterski V, Prentice P & Hughes IA. Consequences of the Chicago 
consensus on disorders of sex development (DSD): current practices 
in Europe. Archives of Disease in Childhood 2010 95 618–623. (https://
doi.org/10.1136/adc.2009.163840)
 20 Creighton S, Chernausek SD, Romao R, Ransley P & Salle JP. Timing 
and nature of reconstructive surgery for disorders of sex development 
– introduction. Journal of Pediatric Urology 2012 8 602–610. (https://
doi.org/10.1016/j.jpurol.2012.10.001)
 21 Official Statistics of Finland. Population: Population structure.  
Helsinki, Finland: Statistics Finland, 2017. (available at: http://www.
stat.fi/til/vaerak/index_en.html)
 22 Bonomi M, Rochira V, Pasquali D, Balercia G, Jannini EA & 
Ferlin A. Klinefelter syndrome (KS): genetics, clinical phenotype 
and hypogonadism. Journal of Endocrinological Investigation 2016 40 
123–134. (https://doi.org/10.1007/s40618-016-0541-6)
 23 Wohlfahrt-Veje C, Boisen KA, Boas M, Damgaard IN, Kai CM, 
Schmidt IM, Chellakooty M, Suomi AM, Toppari J, Skakkebaek NE, 
et al. Acquired cryptorchidism is frequent in infancy and childhood. 
International Journal of Andrology 2009 32 423–428. (https://doi.
org/10.1111/j.1365-2605.2008.00946.x)
 24 Berglund A, Johannsen TH, Stochholm K, Viuff MH, Fedder J, 
Main KM & Gravholt CH. Incidence, prevalence, diagnostic 
delay, and clinical presentation of female 46,XY disorders of sex 
development. Journal of Clinical Endocrinology and Metabolism 2016 
101 4532–4540. (https://doi.org/10.1210/jc.2016-2248)
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0070
http://www.endocrineconnections.org ©2018 The authors
Published by Bioscientifica Ltd
E Kohva et al. DSDs: timing of diagnosis and 
management
6037:4
 25 Hersmus R, Stoop H, White SJ, Drop SLS, Oosterhuis JW, Incrocci L, 
Wolffenbuttel KP & Looijenga LHJ. Delayed recognition of disorders 
of sex development (DSD): a missed opportunity for early diagnosis 
of malignant germ cell tumors. International Journal of Endocrinology 
2012 2012 671209.
 26 Sävendahl L & Davenport ML. Delayed diagnoses of Turner’s 
syndrome: proposed guidelines for change. Journal of Pediatrics 2000 
137 455–459. (https://doi.org/10.1067/mpd.2000.107390)
 27 Ríos Orbañanos I, Vela Desojo A, Martinez-Indart L, Grau Bolado G, 
Rodriguez Estevez A & Rica Echevarria I. Turner syndrome: from 
birth to adulthood. Endocrinología y Nutrición 2015 62 499–506. 
(https://doi.org/10.1016/j.endonu.2015.06.010)
 28 Bojesen A, Juul S & Gravholt CH. Prenatal and postnatal prevalence 
of Klinefelter syndrome: a national registry study. Journal of Clinical 
Endocrinology and Metabolism 2003 88 622–626. (https://doi.
org/10.1210/jc.2002-021491)
 29 Groth KA, Skakkebæk A, Høst C, Gravholt CH & Bojesen A. 
Clinical review: Klinefelter syndrome – a clinical update. Journal of 
Clinical Endocrinology and Metabolism 2013 98 20–30. (https://doi.
org/10.1210/jc.2012-2382)
 30 Herlihy AS & McLachlan RI. Screening for Klinefelter syndrome. 
Current Opinion in Endocrinology, Diabetes and Obesity 2015 22 
224–229. (https://doi.org/10.1097/MED.0000000000000154)
 31 Baena N, De Vigan C, Cariati E, Clementi M, Stoll C, Caballín MR & 
Guitart M. Turner syndrome: evaluation of prenatal diagnosis in 19 
European registries. American Journal of Medical Genetics Part A 2004 
129A 16–20. (https://doi.org/10.1002/ajmg.a.30092)
 32 Hensel KO, Caspers T, Jenke AC, Schuler E & Wirth S. Operative 
management of cryptorchidism: guidelines and reality – a 10-year 
observational analysis of 3587 cases. BMC Pediatrics 2015 15 116. 
(https://doi.org/10.1186/s12887-015-0429-1)
 33 Nah SA, Yeo CSW, How GY, Allen JC, Lakshmi NK, Yap T-L, 
Jacobsen AS, Low Y & Ong CC. Undescended testis: 513 patients’ 
characteristics, age at orchidopexy and patterns of referral. Archives 
of Disease in Childhood 2014 99 401–406. (https://doi.org/10.1136/
archdischild-2013-305225)
 34 Bergbrant S, Omling E, Björk J & Hagander L. Cryptorchidism in 
Sweden: a nationwide study of prevalence, operative management, 
and complications. Journal of Pediatrics 2018 194 197–203.e6. 
(https://doi.org/10.1016/j.jpeds.2017.09.062)
 35 Nilsson R, Omland H, Dahl AA & Johansen TEB. Early outcome of 
orchiopexy and analysis of predictive factors: a retrospective study 
from 2001 to 2010 in a Norwegian regional hospital. Scandinavian 
Journal of Urology 2014 48 474–481. (https://doi.org/10.3109/216818
05.2014.905631)
 36 Kulle A, Krone N, Holterhus PM, Schuler G, Greaves RF, Juul A, de 
Rijke YB, Hartmann MF, Saba A, Hiort O, et al. Steroid hormone 
analysis in diagnosis and treatment of DSD: position paper of EU 
COST Action BM 1303 'DSDnet'. European Journal of Endocrinology 
2017 176 P1–P9. (https://doi.org/10.1530/EJE-16-0953)
 37 Eggers S, Sadedin S, van den Bergen JA, Robevska G, Ohnesorg T, 
Hewitt J, Lambeth L, Bouty A, Knarston IM, Tan TY, et al. Disorders 
of sex development: insights from targeted gene sequencing of a 
large international patient cohort. Genome Biology 2016 17 243. 
(https://doi.org/10.1186/s13059-016-1105-y)
 38 Alhomaidah D, McGowan R & Ahmed SF. The current state of 
diagnostic genetics for conditions affecting sex development. Clinical 
Genetics 2017 91 157–162. (https://doi.org/10.1111/cge.12912)
Received in final form 15 March 2018
Accepted 26 March 2018
Accepted Preprint published online 26 March 2018
This work is licensed under a Creative Commons 
Attribution-NonCommercial 4.0 International 
License.
https://doi.org/10.1530/EC-18-0070
http://www.endocrineconnections.org ©2018 The authors
Published by Bioscientifica Ltd
